Yep, FY24 is the calendar year in the US.
I wouldn't say that I'm "expecting" them to double sales from $26M in 1H24 to $52.5M in 2H24 in order to reach the $78.5M in commercial revenue. Seems impossible, I know! However, I've done some analysis (for the lack of a better word) based on what we've been told and made some assumptions that provides an achievable line of sight to the $78.5M and the profitability goal. I'd say that I'm not ruling two these expectations out yet - I'm possibly even cautiously optimistic at this stage now that GO has been approved.
As you've highlighted, FY23 revenue growth was around 46% and even though Q124 was flat, with RECELL GO, I think there's a good chance that they can at least match that yoy growth in FY24.
All the best with your future research. There's a lot of good info at https://ir.avitamedical.com/ if you're interested.
- Forums
- ASX - By Stock
- Ann: AVITA Medical Announces FDA Approval of RECELL GO
Yep, FY24 is the calendar year in the US.I wouldn't say that I'm...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
|
|||||
Last
$3.01 |
Change
-0.085(2.75%) |
Mkt cap ! $204.9M |
Open | High | Low | Value | Volume |
$3.00 | $3.04 | $2.98 | $233.3K | 77.79K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 205 | $3.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.01 | 4988 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 71 | 3.000 |
3 | 5620 | 2.990 |
4 | 4740 | 2.980 |
3 | 9683 | 2.970 |
1 | 3000 | 2.960 |
Price($) | Vol. | No. |
---|---|---|
3.010 | 1960 | 2 |
3.020 | 12500 | 2 |
3.030 | 6920 | 3 |
3.040 | 7549 | 3 |
3.050 | 5000 | 2 |
Last trade - 11.02am 25/07/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online